Ping‐Chih Hsu

1.6k total citations
69 papers, 1.0k citations indexed

About

Ping‐Chih Hsu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ping‐Chih Hsu has authored 69 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 48 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Ping‐Chih Hsu's work include Lung Cancer Treatments and Mutations (41 papers), Colorectal Cancer Treatments and Studies (19 papers) and Lung Cancer Research Studies (17 papers). Ping‐Chih Hsu is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Colorectal Cancer Treatments and Studies (19 papers) and Lung Cancer Research Studies (17 papers). Ping‐Chih Hsu collaborates with scholars based in Taiwan, United States and China. Ping‐Chih Hsu's co-authors include Cheng‐Ta Yang, Liang You, David M. Jablons, Yi‐Lin Yang, Chih‐Hsi S. Kuo, Zhidong Xu, Yuyuan Dai, Yueh‐Fu Fang, Yucheng Wang and Hui Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Ping‐Chih Hsu

63 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ping‐Chih Hsu Taiwan 16 523 476 396 355 116 69 1.0k
Vicky Pui‐Chi Tin Hong Kong 9 479 0.9× 220 0.5× 459 1.2× 81 0.2× 219 1.9× 11 787
Nicolaos Palaskas United States 8 266 0.5× 316 0.7× 625 1.6× 74 0.2× 290 2.5× 10 898
Stina Mui Singel United States 11 297 0.6× 197 0.4× 336 0.8× 77 0.2× 138 1.2× 26 599
Vishnu Kumarasamy United States 14 360 0.7× 258 0.5× 271 0.7× 68 0.2× 103 0.9× 22 621
David Y. Takeda United States 12 255 0.5× 404 0.8× 895 2.3× 184 0.5× 239 2.1× 19 1.2k
Victor Olivas United States 13 251 0.5× 244 0.5× 451 1.1× 62 0.2× 166 1.4× 19 712
Sorin Armeanu–Ebinger Germany 16 241 0.5× 105 0.2× 467 1.2× 164 0.5× 203 1.8× 45 895
Qiuyuan Wen China 21 245 0.5× 153 0.3× 801 2.0× 106 0.3× 424 3.7× 59 1.1k
Nadia P. Castro United States 16 416 0.8× 75 0.2× 704 1.8× 160 0.5× 257 2.2× 25 1.0k

Countries citing papers authored by Ping‐Chih Hsu

Since Specialization
Citations

This map shows the geographic impact of Ping‐Chih Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ping‐Chih Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ping‐Chih Hsu more than expected).

Fields of papers citing papers by Ping‐Chih Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ping‐Chih Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ping‐Chih Hsu. The network helps show where Ping‐Chih Hsu may publish in the future.

Co-authorship network of co-authors of Ping‐Chih Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Ping‐Chih Hsu. A scholar is included among the top collaborators of Ping‐Chih Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ping‐Chih Hsu. Ping‐Chih Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
5.
6.
Huang, Chi‐Hsien, Chin‐Chou Wang, Fu‐Tsai Chung, et al.. (2024). Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC. Therapeutic Advances in Medical Oncology. 16. 2667340–2667340.
7.
Huang, Chi‐Hsien, Chin‐Chou Wang, Fu‐Tsai Chung, et al.. (2023). Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC. Scientific Reports. 13(1). 20323–20323. 8 indexed citations
8.
9.
Hsu, Ping‐Chih, John Wen‐Cheng Chang, Chen‐Yang Huang, et al.. (2022). Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations. Therapeutic Advances in Respiratory Disease. 16. 2673712059–2673712059. 10 indexed citations
10.
Chang, John Wen‐Cheng, Chen‐Yang Huang, Yueh‐Fu Fang, et al.. (2022). Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI. Cancers. 14(4). 977–977. 11 indexed citations
11.
Kuo, Chih‐Hsi S., Chi‐Hsien Huang, Chin‐Chou Wang, et al.. (2022). Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancers. 14(2). 316–316. 7 indexed citations
12.
Lin, Yu‐Ching, Li‐Chung Chiu, Shih‐Hong Li, et al.. (2022). Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. Therapeutic Advances in Medical Oncology. 14. 4287525310–4287525310. 7 indexed citations
13.
Chiu, Li‐Chung, Ping‐Chih Hsu, Tzung‐Hai Yen, et al.. (2021). Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease. Medicina. 57(11). 1160–1160. 3 indexed citations
14.
Chiu, Li‐Chung, Shu‐Min Lin, Yu‐Lun Lo, et al.. (2021). Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines. 9(7). 689–689. 14 indexed citations
15.
Wang, Chin‐Chou, Chien‐Ying Liu, Chih‐Liang Wang, et al.. (2020). Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer. Thoracic Cancer. 11(6). 1541–1549. 28 indexed citations
16.
Hsu, Ping‐Chih, Chun‐Chieh Wang, Chen‐Te Wu, et al.. (2019). Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study. Thoracic Cancer. 10(8). 1683–1691. 4 indexed citations
17.
Chang, Yu‐Chen, et al.. (2019). The Prevalence of PD-L1 Expression in Lung Cancer. 4(1). 6 indexed citations
18.
Huang, Shih‐Hao, Chin‐Chou Wang, Chien‐Ying Liu, et al.. (2019). Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thoracic Cancer. 10(12). 2274–2281. 3 indexed citations
19.
Hsu, Ping‐Chih, Zhen Huang, Yi‐Lin Yang, et al.. (2018). Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. Journal of Cellular and Molecular Medicine. 22(6). 3073–3085. 26 indexed citations
20.
Zhang, Wenqian, Yuyuan Dai, Ping‐Chih Hsu, et al.. (2017). Targeting YAP in malignant pleural mesothelioma. Journal of Cellular and Molecular Medicine. 21(11). 2663–2676. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vicky Pui‐Chi Tin Breakdown of academic impact, for papers by Nicolaos Palaskas Breakdown of academic impact, for papers by Stina Mui Singel Breakdown of academic impact, for papers by Vishnu Kumarasamy Breakdown of academic impact, for papers by David Y. Takeda Breakdown of academic impact, for papers by Victor Olivas Breakdown of academic impact, for papers by Sorin Armeanu–Ebinger Breakdown of academic impact, for papers by Qiuyuan Wen Breakdown of academic impact, for papers by Nadia P. Castro
Rankless by CCL
2026